REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
Pivotal trial enrollment completed in October; confirmatory trial open and enrolling New 12-month analysis shows all participants demonstrate improved functional outcomes across multiple natural history methods of measurement, when decline is expected Clemidsogene lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026 Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy for chronic retinal disease Enrollment completed in pivotal trials evaluating subretinal delivery of sura-vec in wet AMD; topline data expected Q4 2026 Sura-vec for diabetic retinopathy using suprachoroidal delivery advancing to global pivotal program, supported by positive 2-year Phase II trial data Conference call today at 8:00 a.m. ET ROCKVILLE, Md. Nov. 6, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the third quarter ended September 30, 202
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Regenxbio files $300M mixed shelf offering [Seeking Alpha]Seeking Alpha
- REGENXBIO to Participate in Upcoming Investor Conference [Yahoo! Finance]Yahoo! Finance
- REGENXBIO to Participate in Upcoming Investor ConferencePR Newswire
- REGENXBIO (NASDAQ:RGNX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RGNX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
RGNX
Earnings
- 11/6/25 - Beat
RGNX
Sec Filings
- 11/26/25 - Form S-3
- 11/6/25 - Form 8-K
- 11/6/25 - Form 10-Q
- RGNX's page on the SEC website